Newsfeeds - Spark Newswire

1 minute read

Veru Q3 EPS $(0.03) Beats $(0.06) Estimate, Sales $17.70M Beat $14.10M Estimate

Today, 2:33 PM

Veru (NASDAQ:VERU) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 40 percent increase over losses of $(0.05) per share from the same period

VERU

15 minute read

Earnings Scheduled For August 12, 2021

By Benzinga Insights

Today, 2:33 PM

Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.

AACG

2 minute read

Earnings

Earnings Outlook For Veru

By Benzinga Insights

Today, 2:33 PM

On Thursday, August 12, Veru (NASDAQ:VERU) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

VERU

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 2:33 PM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

1 minute read

FDA
News

Veru Announces Presentation Of Phase 1b/2 Clinical Study Update For Sabizabulin (VERU-111) In Men With Metastatic Castration Resistant Prostate Cancer At The 2021 European Association Of Urology Annual Congress

By Benzinga Newsdesk

Today, 2:33 PM

Veru Inc. (NASDAQ:VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase

VERU

7 minute read

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes

By Shanthi Rexaline

Today, 2:33 PM

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.

ADAP

1 minute read

Uncategorized

Return On Capital Employed Overview: Veru

By Benzinga Insights

Today, 2:33 PM

During Q2, Veru (NASDAQ:VERU) brought in sales totaling $13.34 million. However, earnings decreased 289.37%, resulting in a loss of $1.47 million. In Q1, Veru earned $777.00 thousand, and total sales reached $14.62 million.

VERU